MDT vs SYK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and SYK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and SYK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.

Full MDT guide

Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). Its products include surgical instruments and navigation, endoscopy and communications systems, patient handling and emergency medical equipment, minimally invasive vascular and neurovascular devices, and orthopaedic implants for hips, knees, and trauma. The company's signature differentiator is Mako robotic-arm assisted surgery, which pulls hospitals into Stryker's ecosystem of implants and enabling technology; in early 2026 Stryker recast its Orthopaedics operations into a new Ortho Tech business that pairs orthopaedic instruments with Mako and enabling technologies.

Full SYK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
• SYK drivers: Mako robotics and enabling technology; MedSurg and Neurotechnology breadth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For SYK, stryker trades at a premium valuation, so any slowdown in organic growth or margin progress can pressure the multiple.

Pick MDT if you believe its drivers more; SYK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MDT and SYK guides.

MDT. Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.

SYK. Stryker trades around $330 per share with a market cap near $127 billion, a premium franchise multiple that reflects its consistent growth record. Trailing P/E has run in the high-30s while the forward P/E sits closer to 22x on expected earnings growth. The Q1 2026 cyber incident dented near-term results, but management reaffirmed full-year organic growth guidance of 8.0% to 9.5%.

Headline figures (approximate, early 2026): MDT shows revenue (ttm) ~$33 billion, operating margin ~20% (non-GAAP higher; GAAP affected by amortization), net income (ttm) ~$4.5 billion, eps (ttm) ~$3.50 GAAP; non-GAAP higher; SYK shows revenue (2025) ~$25.1B, q1 2026 revenue ~$6.0B (+2.6% YoY), 2026 adj. eps guidance ~$14.90-$15.10, market cap ~$127B.

MDT and SYK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and SYK exposure against your real portfolio. It is not an investment adviser.